Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women

被引:284
作者
Eliassen, A. Heather
Missmer, Stacey A.
Tworoger, Shelley S.
Spiegelman, Donna
Barbieri, Robert L.
Dowsett, Mitch
Hankinson, Susan E.
机构
[1] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Channing Lab, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Royal Marsden Hosp, Dept Biochem, London SW3 6JJ, England
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2006年 / 98卷 / 19期
关键词
D O I
10.1093/jnci/djj376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Higher levels of endogenous sex steroid hormones are associated with increased risks of breast cancer in postmenopausal women. Data for premenopausal women are sparse, in part because of the complexity of measuring hormone levels that vary cyclically. We prospectively evaluated associations between plasma sex hormone levels and breast cancer risk among premenopausal women in a case-control study nested within the Nurses' Health Study II. Methods: From 1996 to 1999, blood samples were collected from 18 521 premenopausal women during the early follicular and mid-luteal phases of their menstrual cycles. A total of 197 cases of breast cancer were diagnosed among these women after blood collection and before June 1, 2003; these case subjects were matched to 394 control subjects. Logistic regression models, controlling for breast cancer risk factors, were used to calculate relative risks (RRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: Women in the highest (versus the lowest) quartiles of follicular total and free estradiol levels had statistically significantly increased risks of breast cancer (RR = 2.1 [95% CI = 1.1 to 4.1], P-trend = .08, and RR = 2.4 [95% CI = 1.3 to 4.5], P-trend = .01, respectively); the associations were stronger for invasive breast cancer and for estrogen and progesterone receptor-positive (ER+/PR+) tumors. Luteal estradiol levels were not associated with breast cancer risk. Higher levels of total and free testosterone and androstenedione in both menstrual cycle phases were associated with modest, non-statistically significant increases in overall risk of breast cancer and with stronger, statistically significant increases in risks of invasive and ER+/PR+ cancers (e.g., RR of invasive cancers for the top [versus bottom] quartile of luteal total testosterone levels = 2.0 [95% CI = 1.1 to 3.6], P-trend = .05, and RR of ER+/PR+ cancers = 2.9 [95% CI = 1.4 to 6.9] P-trend = .02). Levels of estrone, estrone sulfate, progesterone, and sex hormone-binding globulin were not associated with breast cancer risk. The absolute number of cases observed over 3 years were 30 among women in the lowest 25% of follicular total estradiol levels and 50 among women in the highest 25%. Conclusions: Levels of circulating estrogens and androgens may be important in the etiology of premenopausal breast cancer.
引用
收藏
页码:1406 / 1415
页数:10
相关论文
共 57 条
[1]  
[Anonymous], 1973, HDB PHYSL SECTION 7
[2]   APPLICATION OF A METHOD FOR ESTIMATING DAY OF OVULATION USING URINARY ESTROGEN AND PROGESTERONE METABOLITES [J].
BAIRD, DD ;
MCCONNAUGHEY, DR ;
WEINBERG, CR ;
MUSEY, PI ;
COLLINS, DC ;
KESNER, JS ;
KNECHT, EA ;
WILCOX, AJ .
EPIDEMIOLOGY, 1995, 6 (05) :547-550
[3]   INFLUENCE OF MENSTRUAL-CYCLE, PARITY AND ORAL-CONTRACEPTIVE USE ON STEROID-HORMONE RECEPTORS IN NORMAL BREAST [J].
BATTERSBY, S ;
ROBERTSON, BJ ;
ANDERSON, TJ ;
KING, RJB ;
MCPHERSON, K .
BRITISH JOURNAL OF CANCER, 1992, 65 (04) :601-607
[4]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[5]   Epidemiology of endocrine-related risk factors for breast cancer [J].
Bernstein, L .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2002, 7 (01) :3-15
[6]   Intratumoral aromatase model: The effects of letrozole (CGS 20267) [J].
Brodie, A ;
Lu, Q ;
Yue, W ;
Wang, JP ;
Liu, Y .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (Suppl 1) :S23-S26
[7]   A LINK BETWEEN BREAST-CANCER AND LOCAL ESTROGEN BIOSYNTHESIS SUGGESTED BY QUANTIFICATION OF BREAST ADIPOSE-TISSUE AROMATASE CYTOCHROME-P450 TRANSCRIPTS USING COMPETITIVE POLYMERASE CHAIN-REACTION AFTER REVERSE TRANSCRIPTION [J].
BULUN, SE ;
PRICE, TM ;
AITKEN, J ;
MAHENDROO, MS ;
SIMPSON, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (06) :1622-1628
[8]   Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma [J].
Chen, WY ;
Hankinson, SE ;
Schnitt, SJ ;
Rosner, BA ;
Holmes, MD ;
Colditz, GA .
CANCER, 2004, 101 (07) :1490-1500
[9]   Breast cancer risk reduction: Strategies for women at increased risk [J].
Chlebowski, RT .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :519-540
[10]   Effects of a progestogen on normal human breast epithelial cell apoptosis in vitro and in vivo [J].
Desreux, J ;
Kebers, F ;
Noël, A ;
Francart, D ;
Van Cauwenberge, H ;
Heinen, V ;
Peyrollier, K ;
Thomas, JL ;
Bernard, AM ;
Paris, J ;
Delansorne, R ;
Foidart, JM .
BREAST, 2003, 12 (02) :142-149